bempikibart   Click here for help

GtoPdb Ligand ID: 13725

Synonyms: ADX-914 | ADX914
Immunopharmacology Ligand
Compound class: Antibody
Comment: Bempikibart (ADX-914; Q32 Bio) is a fully human anti-IL-7 receptor alpha (IL-7Rα) monoclonal antibody [1]. It was designed for potential disease-modifying anti-inflammatory action in autoimmune conditions. Bempikibart blocks IL-7 and thymic stromal lymphopoietin (TSLP) from binding to the common IL-7Rα subunit of their endogenous receptors, thus reducing receptor activation and re-regulating immune homeostasis.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Bempikibart failed to demonstrate efficacy in a phase 2b study of patients with moderate to severe atopic dermatitis, but development in alopecia areata is continuing (as of Jan 2025).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04485481 Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Phase 1 Interventional Q32 Bio Inc.
NCT05509023 Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2 Interventional Q32 Bio Inc.
NCT06018428 Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata Phase 2 Interventional Q32 Bio Inc.